Diabetic Retinopathy
Diabetic retinopathy (DR) is a progressive neurovascular complication of both type 1 and type 2 diabetes mellitus and a leading cause of preventable blindness in working-age adults worldwide. Chronic hyperglycemia drives retinal microvascular injury through oxidative stress, inflammation, and vascular dysfunction, leading to pericyte loss, blood-retinal barrier (BRB) breakdown, and ultimately to macular edema and pathological neovascularization. Disease progresses from nonproliferative stages (NPDR), in which retinal vessels are damaged but neovascularization has not yet occurred, to proliferative diabetic retinopathy (PDR), characterized by VEGF-driven abnormal neovascularization. Diabetic macular edema (DME), due to BRB breakdown with fluid accumulation in the macula, is the major cause of moderate vision loss and can occur at any stage. Contemporary management rests on systematic screening, glycemic and cardiovascular risk-factor control, intravitreal anti-VEGF therapy for center-involving DME, and panretinal photocoagulation (PRP) for high-risk PDR.
Ask OpenScientist
Ask a research question about Diabetic Retinopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Classifications
Subtypes
3Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Pathophysiology
5Show evidence (2 references)
Show evidence (1 reference)
Show evidence (3 references)
Show evidence (2 references)
Show evidence (2 references)
Pathograph
Phenotypes
6Eye 3
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Other 3
Show evidence (1 reference)
Show evidence (2 references)
Show evidence (1 reference)
Medical Actions
3Show evidence (3 references)
Show evidence (2 references)
Show evidence (1 reference)
Environmental Factors
4Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (2 references)
Clinical Trials
1Show evidence (1 reference)
Source YAML
click to showname: Diabetic Retinopathy
creation_date: '2026-06-16T00:00:00Z'
category: Complex
description: >
Diabetic retinopathy (DR) is a progressive neurovascular complication of both
type 1 and type 2 diabetes mellitus and a leading cause of preventable blindness
in working-age adults worldwide. Chronic hyperglycemia drives retinal microvascular
injury through oxidative stress, inflammation, and vascular dysfunction, leading
to pericyte loss, blood-retinal barrier (BRB) breakdown, and ultimately to
macular edema and pathological neovascularization. Disease progresses from
nonproliferative stages (NPDR), in which retinal vessels are damaged but
neovascularization has not yet occurred, to proliferative diabetic retinopathy
(PDR), characterized by VEGF-driven abnormal neovascularization. Diabetic macular
edema (DME), due to BRB breakdown with fluid accumulation in the macula, is the
major cause of moderate vision loss and can occur at any stage. Contemporary
management rests on systematic screening, glycemic and cardiovascular risk-factor
control, intravitreal anti-VEGF therapy for center-involving DME, and panretinal
photocoagulation (PRP) for high-risk PDR.
disease_term:
preferred_term: Diabetic retinopathy
term:
id: MONDO:0005266
label: diabetic retinopathy
parents:
- Retinal Disease
- Complication of Diabetes
has_subtypes:
- name: Nonproliferative Diabetic Retinopathy
display_name: Nonproliferative Diabetic Retinopathy (NPDR)
description: >
Early-to-moderate stage of DR in which retinal microvascular lesions are
present (microaneurysms, intraretinal hemorrhages, hard exudates, cotton-wool
spots, venous beading, intraretinal microvascular abnormalities) but
pathological neovascularization has not yet developed. Eyes with NPDR have
not yet developed neovascularization. Encompasses background (mild), moderate,
and the milder end of severe NPDR.
subtype_term:
preferred_term: nonproliferative diabetic retinopathy
term:
id: MONDO:0001661
label: background diabetic retinopathy
evidence:
- reference: PMID:39673354
reference_title: "Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Two trials were of patients with non-proliferative diabetic retinopathy; all others were in proliferative diabetic retinopathy."
explanation: Systematic review of 14 RCTs recognizes non-proliferative diabetic retinopathy as a distinct clinical stage from PDR, validating the NPDR/PDR staging framework.
- name: Severe Nonproliferative Diabetic Retinopathy
display_name: Severe Nonproliferative Diabetic Retinopathy (Severe NPDR)
description: >
Advanced NPDR characterized by extensive microvascular lesions meeting the
4-2-1 rule (≥20 intraretinal hemorrhages in each of 4 quadrants, venous
beading in ≥2 quadrants, or prominent intraretinal microvascular abnormalities
in ≥1 quadrant) without neovascularization. Carries high risk of progression
to PDR (approximately 50% within 1 year without treatment) and warrants close
follow-up and consideration of early anti-VEGF therapy.
subtype_term:
preferred_term: severe nonproliferative diabetic retinopathy
term:
id: MONDO:0004687
label: severe nonproliferative diabetic retinopathy
evidence:
- reference: PMID:29776671
reference_title: "Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Vision loss from DR can be prevented with broad-level public health strategies, but these need to be tailored to a country's and population's resource setting."
explanation: ICO guidelines define DR staging from mild NPDR through severe NPDR to PDR as the core clinical framework, and recommend closer follow-up and timely intervention for severe NPDR.
- name: Proliferative Diabetic Retinopathy
display_name: Proliferative Diabetic Retinopathy (PDR)
description: >
Most advanced stage of DR, defined by the presence of pathological
neovascularization arising from the optic disc or retinal surface in response
to ischemia-driven VEGF overexpression. New vessels grow into the vitreous
cavity, where they may rupture (vitreous hemorrhage) or promote traction
through fibrovascular membrane contraction (tractional retinal detachment),
causing severe vision loss. Panretinal photocoagulation (PRP) is the
established primary treatment for high-risk PDR.
subtype_term:
preferred_term: proliferative diabetic retinopathy
term:
id: MONDO:0001660
label: proliferative diabetic retinopathy
evidence:
- reference: PMID:39673354
reference_title: "Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most severe form, proliferative diabetic retinopathy, carries a high risk of vision loss, vitreous haemorrhage, macular oedema and other harms. Panretinal photocoagulation is the primary treatment for proliferative diabetic retinopathy."
explanation: HTA systematic review defines PDR as the most severe DR stage and confirms PRP as its primary treatment, establishing neovascularization-driven complications as the defining features.
pathophysiology:
- name: Hyperglycemia-Induced Oxidative Stress and Metabolic Pathway Activation
description: >
Chronic hyperglycemia activates four major biochemical pathways—increased
polyol pathway flux, increased advanced glycation end product (AGE) formation,
activation of protein kinase C (PKC) isoforms, and increased hexosamine
pathway flux—all of which converge on a single unifying mechanism:
overproduction of superoxide by the mitochondrial electron-transport chain.
This excess reactive oxygen species (ROS) production drives oxidative stress
that initiates the downstream cascade of retinal neurovascular injury, BRB
disruption, neurodegeneration, and angiogenesis. DR is now recognized as a
neurovascular disorder arising from chronic hyperglycemia-induced oxidative
stress, inflammation, and vascular dysfunction.
evidence:
- reference: PMID:11742414
reference_title: "Biochemistry and molecular cell biology of diabetic complications."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Four main molecular mechanisms have been implicated in glucose-mediated vascular damage. All seem to reflect a single hyperglycaemia-induced process of overproduction of superoxide by the mitochondrial electron-transport chain."
explanation: Landmark mechanistic review establishes mitochondrial superoxide overproduction as the unifying mechanism linking hyperglycemia to all four major biochemical pathways of diabetic microvascular damage.
- reference: PMID:40722979
reference_title: "Modulation of Oxidative Stress in Diabetic Retinopathy: Therapeutic Role of Natural Polyphenols."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diabetic retinopathy (DR), a leading cause of blindness in working-age adults, arises from chronic hyperglycemia-induced oxidative stress, inflammation, and vascular dysfunction."
explanation: Contemporary review confirms DR pathogenesis as arising from hyperglycemia-driven oxidative stress, inflammation, and vascular dysfunction, framing it as a neurovascular disorder.
biological_processes:
- preferred_term: response to oxidative stress
term:
id: GO:0006979
label: response to oxidative stress
modifier: INCREASED
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
downstream:
- target: Retinal Vascular Cell Injury and Pericyte Loss
causal_link_type: DIRECT
description: Mitochondrial ROS overproduction directly damages retinal pericytes and endothelial cells, initiating the microvascular degeneration that underlies DR.
- target: Neuroinflammatory Cytokine and Microglial Activation
causal_link_type: DIRECT
description: Oxidative stress activates NF-κB signaling and the NLRP3 inflammasome, driving cytokine production and microglial activation in the retina.
- name: Retinal Vascular Cell Injury and Pericyte Loss
description: >
Sustained oxidative and metabolic injury selectively destroys retinal pericytes,
the stabilizing mural cells of the microvasculature, while simultaneously
damaging vascular endothelial cells. Pericyte loss is the earliest
histopathological hallmark of DR and destabilizes the retinal microvasculature
by disrupting ANGPT2-Tie2 signaling: interaction between angiopoietin 2 and
the Tie2 receptor results in aberrant signaling that further drives pericyte
loss, neovascularization, and inflammation. Progressive capillary closure and
acellular capillary formation lead to retinal ischemia, which upregulates
VEGF as the pro-angiogenic signal driving PDR.
evidence:
- reference: PMID:39519401
reference_title: "Molecular and Cellular Mechanisms Involved in the Pathophysiology of Retinal Vascular Disease-Interplay Between Inflammation and Oxidative Stress."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Interaction between angiopoietin 2 and the Tie2 receptor results in aberrant Tie2 signaling, resulting in loss of pericytes, neovascularization, and inflammation."
explanation: Review identifies ANGPT2-Tie2 dysregulation as a key molecular mechanism driving pericyte loss, neovascularization, and inflammation in retinal vascular disease including DR.
cell_types:
- preferred_term: pericyte
term:
id: CL:0000669
label: pericyte
- preferred_term: retinal vascular endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: angiogenesis
term:
id: GO:0001525
label: angiogenesis
modifier: INCREASED
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
downstream:
- target: Blood-Retinal Barrier Breakdown
causal_link_type: DIRECT
description: Pericyte loss and endothelial cell injury disrupt tight junctions, causing blood-retinal barrier failure and increased vascular permeability.
- target: VEGF-Driven Retinal Neovascularization
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Progressive pericyte loss and capillary closure cause retinal ischemia, which upregulates VEGF as the primary angiogenic signal.
description: Ischemia from capillary degeneration drives VEGF overexpression, triggering pathological neovascularization that defines PDR.
- name: Neuroinflammatory Cytokine and Microglial Activation
description: >
A persistent pro-inflammatory milieu in the diabetic retina is maintained by
elevated TNF-α, IL-1β, and IL-6, alongside activation of resident microglia.
NF-κB and Toll-like receptor (TLR) signaling amplify cytokine production,
and oxidative stress interacts with inflammation in a self-amplifying cycle
in which each factor amplifies the other. This inflammatory environment
promotes BRB breakdown, endothelial dysfunction, and retinal neurodegeneration.
evidence:
- reference: PMID:39519401
reference_title: "Molecular and Cellular Mechanisms Involved in the Pathophysiology of Retinal Vascular Disease-Interplay Between Inflammation and Oxidative Stress."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Toll-like receptor signaling and nuclear factor-kappa B are important factors in the dysregulation of the immune response in retinal vascular diseases."
explanation: Review identifies TLR/NF-kB-driven cytokine signaling and microglial activation as key mediators of neuroinflammation, BRB breakdown, and neovascularization in retinal vascular disease.
- reference: PMID:39519401
reference_title: "Molecular and Cellular Mechanisms Involved in the Pathophysiology of Retinal Vascular Disease-Interplay Between Inflammation and Oxidative Stress."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Increased production of reactive oxygen species and oxidative damage follow inflammation and together create a vicious cycle because each factor amplifies the other."
explanation: Review documents the ROS-inflammation positive feedback loop as a core feature of retinal vascular disease pathogenesis.
- reference: PMID:42314860
reference_title: "Predicting the progression of proliferative diabetic retinopathy: Pathophysiology, imaging phenotypes, and determinants of disease persistence despite therapy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "PDR is contextualised as a multifactorial neurovascular and inflammatory disease, integrating data on hypoxia-driven angiogenesis, glial activation, microvascular rarefaction, neurodegeneration, and vitreoretinal interface remodelling."
explanation: Comprehensive survey contextualizes PDR pathogenesis as a multifactorial neurovascular-inflammatory disease integrating hypoxia, glial activation, and neurodegeneration, supporting the central role of neuroinflammation.
cell_types:
- preferred_term: microglial cell
term:
id: CL:0000129
label: microglial cell
biological_processes:
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
modifier: INCREASED
- preferred_term: cytokine-mediated signaling pathway
term:
id: GO:0019221
label: cytokine-mediated signaling pathway
modifier: INCREASED
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
downstream:
- target: Blood-Retinal Barrier Breakdown
causal_link_type: DIRECT
description: Inflammatory cytokines disrupt tight junctions between retinal endothelial cells, increasing vascular permeability and contributing to BRB failure.
- name: Blood-Retinal Barrier Breakdown
description: >
Disruption of the inner blood-retinal barrier (formed by retinal vascular
endothelium with tight junctions) by VEGF, inflammatory cytokines, and loss
of pericyte support allows plasma proteins and fluid to leak into the retinal
parenchyma. Oxidative stress is a key driver of BRB disruption, which
also promotes neurodegeneration and angiogenesis. BRB breakdown is the
immediate cause of diabetic macular edema (DME) through fluid accumulation
in the macular subfield, and contributes to ischemia through progressive
endothelial dysfunction.
evidence:
- reference: PMID:40722979
reference_title: "Modulation of Oxidative Stress in Diabetic Retinopathy: Therapeutic Role of Natural Polyphenols."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Emerging evidence highlights oxidative stress as a key driver of DR pathogenesis, disrupting the blood-retinal barrier (BRB), promoting neurodegeneration and angiogenesis."
explanation: Review identifies oxidative stress-driven BRB disruption as a key mechanistic step linking hyperglycemia to neurodegeneration and angiogenesis in DR.
- reference: PMID:38264181
reference_title: "Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diabetic macular edema (DME) is a major cause of vision impairment in diabetic individuals, characterized by fluid accumulation in the macula due to a breakdown of the blood-retinal barrier (BRB)."
explanation: Clinical review confirms BRB breakdown as the direct pathophysiological cause of DME, linking endothelial dysfunction to macular fluid accumulation and vision impairment.
biological_processes:
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
modifier: INCREASED
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
downstream:
- target: Macular Edema
causal_link_type: DIRECT
description: BRB failure allows plasma constituents to leak into the macular area, causing retinal thickening and diabetic macular edema, the major cause of moderate vision impairment in DR.
- name: VEGF-Driven Retinal Neovascularization
description: >
Extensive retinal ischemia from capillary closure drives upregulation of
vascular endothelial growth factor A (VEGF-A), the central molecular mediator
of pathological neovascularization that defines PDR. VEGF is recognized as
a crucial and central molecule in abnormal neovascularization, and anti-VEGF
therapy is now the most successful form of treatment for retinal vascular
disorders including DR. Notch signaling and hypoxia-inducible factors (HIFs)
also contribute to pathological vessel growth. New fibrovascular membranes
grow from the optic disc and retinal surface into the vitreous cavity,
where rupture causes vitreous hemorrhage and contracture causes tractional
retinal detachment.
evidence:
- reference: PMID:39519401
reference_title: "Molecular and Cellular Mechanisms Involved in the Pathophysiology of Retinal Vascular Disease-Interplay Between Inflammation and Oxidative Stress."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Vascular endothelial growth factor (VEGF) is recognized as a crucial and central molecule in abnormal neovascularization and a key phenomenon in retinal vascular occlusion; thus, anti-VEGF therapy is now the most successful form of treatment for these disorders."
explanation: Review establishes VEGF as the central driver of pathological neovascularization in retinal vascular disease and explains why anti-VEGF therapy is the primary treatment modality.
- reference: PMID:42314860
reference_title: "Predicting the progression of proliferative diabetic retinopathy: Pathophysiology, imaging phenotypes, and determinants of disease persistence despite therapy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Histopathological and multimodal imaging characteristics of neovascular complexes and the vitreoretinal interface are described, highlighting how phenotypes on colour fundus photography, widefield fluorescein angiography, optical coherence tomography (OCT), and OCT angiography relate to ischemic burden and clinical behaviour."
explanation: Recent comprehensive survey documents the histopathological and multimodal imaging characteristics of neovascular complexes in PDR, linking ischemic burden to neovascular phenotypes across imaging modalities.
biological_processes:
- preferred_term: angiogenesis
term:
id: GO:0001525
label: angiogenesis
modifier: INCREASED
cell_types:
- preferred_term: retinal vascular endothelial cell
term:
id: CL:0000115
label: endothelial cell
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
downstream:
- target: Vitreous Hemorrhage
causal_link_type: DIRECT
description: Fragile neovascular vessels on the retinal surface and vitreous face rupture, causing vitreous hemorrhage and acute vision loss in PDR.
phenotypes:
- name: Visual Impairment
description: >
Progressive loss of vision is the primary clinical consequence of DR.
Early DR is often asymptomatic, but macular edema and PDR-related complications
cause significant functional impairment. DR is a major complication of diabetes
mellitus and a leading cause of vision loss in working middle-aged adults globally.
phenotype_term:
preferred_term: Visual impairment
term:
id: HP:0000505
label: Visual impairment
evidence:
- reference: PMID:29776671
reference_title: "Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diabetic retinopathy (DR) is a major complication of DM and a leading cause of vision loss in working middle-aged adults."
explanation: ICO guidelines establish DR as a leading cause of vision loss in working-age adults, making visual impairment the primary clinical outcome.
- name: Macular Edema
description: >
Fluid accumulation in the macula due to BRB breakdown; center-involving
diabetic macular edema (CI-DME) is the most common cause of moderate vision
loss in DR and can occur at any stage of retinopathy. Characterized by
retinal thickening of the central 1 mm subfield on optical coherence
tomography. Anti-VEGF is the standard of care for CI-DME.
phenotype_term:
preferred_term: Diabetic macular edema
term:
id: HP:0040049
label: Macular edema
evidence:
- reference: PMID:38264181
reference_title: "Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diabetic macular edema (DME) is a major cause of vision impairment in diabetic individuals, characterized by fluid accumulation in the macula due to a breakdown of the blood-retinal barrier (BRB)."
explanation: Clinical review confirms DME as a major cause of vision impairment in diabetes characterized by BRB-driven fluid accumulation in the macula.
- name: Retinal Hemorrhage
description: >
Intraretinal hemorrhages are a hallmark of NPDR, arising from damaged and
leaking retinal capillaries. Dot-blot hemorrhages occur in the deeper retinal
layers and flame-shaped hemorrhages occur in the superficial nerve fiber layer.
Vitreous hemorrhage from ruptured neovascular vessels is a major complication
of PDR.
phenotype_term:
preferred_term: Retinal hemorrhage
term:
id: HP:0000573
label: Retinal hemorrhage
evidence:
- reference: PMID:39673354
reference_title: "Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most severe form, proliferative diabetic retinopathy, carries a high risk of vision loss, vitreous haemorrhage, macular oedema and other harms."
explanation: HTA systematic review confirms vitreous hemorrhage from ruptured neovascular vessels as a major vision-threatening complication of PDR.
- name: Vitreous Hemorrhage
description: >
Rupture of fragile neovascular vessels in PDR causes blood to enter the
vitreous cavity. Presents as sudden painless vision loss ranging from floaters
to complete visual obscuration. A major complication of PDR and a key
endpoint in comparative treatment trials.
phenotype_term:
preferred_term: Vitreous hemorrhage
term:
id: HP:0007902
label: Vitreous hemorrhage
evidence:
- reference: PMID:39673354
reference_title: "Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Anti-vascular endothelial growth factor was superior to panretinal photocoagulation at preventing macular oedema (relative risk 0.29, 95% confidence interval 0.18 to 0.49) and vitreous haemorrhage (relative risk 0.77, 95% confidence interval 0.61 to 0.99)."
explanation: Network meta-analysis of 14 RCTs demonstrates vitreous hemorrhage as a major measurable outcome in PDR trials, with anti-VEGF significantly reducing its relative risk vs. PRP.
- reference: PMID:42314860
reference_title: "Predicting the progression of proliferative diabetic retinopathy: Pathophysiology, imaging phenotypes, and determinants of disease persistence despite therapy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Despite advances in screening and treatment, including panretinal photocoagulation (PRP), intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and pars plana vitrectomy (PPV), outcomes remain heterogeneous: many eyes stabilise, whereas others progress to vitreous hemorrhage, tractional retinal detachment or neovascular glaucoma despite apparently adequate therapy."
explanation: Recent survey documents treatment-resistant PDR despite current therapies, with vitreous hemorrhage and tractional retinal detachment as major complications in eyes with inadequate treatment response.
subtype: Proliferative Diabetic Retinopathy
- name: Tractional Retinal Detachment
description: >
Fibrovascular membrane contraction in PDR creates traction on the retina,
causing it to separate from the underlying retinal pigment epithelium and
choroid. Most common in advanced PDR with extensive fibrovascular proliferation.
Threatens central vision if the macula is involved. A major vision-threatening
complication despite treatment and a persistent challenge in treatment-resistant
PDR.
phenotype_term:
preferred_term: Tractional retinal detachment
term:
id: HP:0007917
label: Tractional retinal detachment
evidence:
- reference: PMID:42314860
reference_title: "Predicting the progression of proliferative diabetic retinopathy: Pathophysiology, imaging phenotypes, and determinants of disease persistence despite therapy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Despite advances in screening and treatment, including panretinal photocoagulation (PRP), intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and pars plana vitrectomy (PPV), outcomes remain heterogeneous: many eyes stabilise, whereas others progress to vitreous hemorrhage, tractional retinal detachment or neovascular glaucoma despite apparently adequate therapy."
explanation: Recent comprehensive survey identifies tractional retinal detachment as a persistent vision-threatening complication in treatment-resistant PDR, despite multiple therapeutic modalities.
subtype: Proliferative Diabetic Retinopathy
- name: Neovascular Glaucoma
description: >
Abnormal fibrovascular tissue (neovascularization of the iris and anterior
chamber angle) in advanced PDR obstructs aqueous outflow through the trabecular
meshwork, causing secondary glaucoma with elevated intraocular pressure. Results
from severe retinal ischemia driving VEGF production that stimulates iris neovascularization.
A serious late complication of PDR with poor prognosis and risk of blindness from
combined optic nerve damage and macular dysfunction.
phenotype_term:
preferred_term: Neovascular glaucoma
term:
id: HP:0000501
label: Glaucoma
evidence:
- reference: PMID:42314860
reference_title: "Predicting the progression of proliferative diabetic retinopathy: Pathophysiology, imaging phenotypes, and determinants of disease persistence despite therapy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Despite advances in screening and treatment, including panretinal photocoagulation (PRP), intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and pars plana vitrectomy (PPV), outcomes remain heterogeneous: many eyes stabilise, whereas others progress to vitreous hemorrhage, tractional retinal detachment or neovascular glaucoma despite apparently adequate therapy."
explanation: Recent comprehensive survey identifies neovascular glaucoma as a major late complication in treatment-resistant PDR, highlighting the severe consequences of uncontrolled iris neovascularization and retinal ischemia.
subtype: Proliferative Diabetic Retinopathy
environmental:
- name: Chronic Hyperglycemia
notes: >
The primary modifiable risk factor for DR onset and progression. Poor glycemic
control (elevated HbA1c) is among the strongest independent predictors of DR
development. Landmark trials (DCCT for type 1; UKPDS for type 2) established
that intensive glycemic control substantially reduces DR incidence and
progression. ADA recommends achieving individualized glycemic targets to
reduce DR risk.
evidence:
- reference: PMID:39550444
reference_title: "Prevalence of diabetic retinopathy and its associated risk factors among adults in Ethiopia: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "poor glycemic control (AOR = 3.83, 95% CI: 1.62-6.04), and positive proteinuria (AHR = 1.55, 95% CI: 1.02-2.07) were risk factors for diabetic retinopathy."
explanation: Meta-analysis quantifies poor glycemic control as conferring ~3.8-fold odds of DR, establishing it as the primary modifiable systemic risk factor.
- name: Diabetes Duration
notes: >
Duration of diabetes is among the strongest predictors of DR onset; risk
increases substantially with each decade. Virtually all patients with type 1
diabetes develop some degree of DR after 20 years of disease.
evidence:
- reference: PMID:39550444
reference_title: "Prevalence of diabetic retinopathy and its associated risk factors among adults in Ethiopia: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Ten years and longer with diabetes (AOR = 4.36, 95% CI: 1.71-7.01), hypertension (AOR = 2.54, 95% CI: 1.45-3.63), poor glycemic control (AOR = 3.83, 95% CI: 1.62-6.04), and positive proteinuria (AHR = 1.55, 95% CI: 1.02-2.07) were risk factors for diabetic retinopathy."
explanation: Meta-analysis demonstrates that ≥10 years of diabetes confers over 4-fold adjusted odds of DR, making duration the strongest identified risk factor in this cohort.
- name: Hypertension
notes: >
Co-existing hypertension accelerates retinal microvascular damage and DR
progression. Blood pressure control (target <130/80 mmHg per ADA) reduces DR
progression risk and is a key element of systemic management.
evidence:
- reference: PMID:39550444
reference_title: "Prevalence of diabetic retinopathy and its associated risk factors among adults in Ethiopia: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "hypertension (AOR = 2.54, 95% CI: 1.45-3.63), poor glycemic control (AOR = 3.83, 95% CI: 1.62-6.04), and positive proteinuria (AHR = 1.55, 95% CI: 1.02-2.07) were risk factors for diabetic retinopathy."
explanation: Meta-analysis identifies hypertension as an independent risk factor conferring ~2.5-fold adjusted odds of DR, supporting blood pressure control as a protective intervention.
- name: Nephropathy and Proteinuria
notes: >
Diabetic nephropathy co-occurs with retinopathy due to shared microvascular
vulnerability. Proteinuria is an independent predictor of DR risk and
progression, and reflects systemic endothelial dysfunction.
evidence:
- reference: PMID:39550444
reference_title: "Prevalence of diabetic retinopathy and its associated risk factors among adults in Ethiopia: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Retinopathy affects one in four patients with diabetes. Diabetic patients with longer duration, hypertension, poor glycemic control, and positive proteinuria should receive special care."
explanation: Meta-analysis concludes that DR affects one in four patients with diabetes, and identifies proteinuria alongside glycemia, hypertension, and duration as factors requiring intensified management.
- reference: PMID:42314860
reference_title: "Predicting the progression of proliferative diabetic retinopathy: Pathophysiology, imaging phenotypes, and determinants of disease persistence despite therapy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Systemic, ocular, imaging, biomarker, and genetic factors associated with progression from non-proliferative diabetic retinopathy to PDR and with progression within established PDR after PRP, anti-VEGF therapy, and PPV are critically appraised. Across modalities, younger age, diabetes duration, poor glycaemic control, renal disease, extensive non-perfusion, high neovascular burden, complex fibrovascular proliferation, and incomplete or unsustained treatment consistently emerge as determinants of guarded outcomes."
explanation: Recent comprehensive survey identifies renal disease (along with diabetes duration, glycemic control, and treatment intensity) as consistent determinants of poor PDR progression outcomes.
treatments:
- name: Intravitreal Anti-VEGF Therapy
therapeutic_modality: MONOCLONAL_ANTIBODY
description: >
First-line therapy for center-involving diabetic macular edema (CI-DME) and
vision-threatening PDR complications. Agents (ranibizumab, bevacizumab,
aflibercept, faricimab) neutralize VEGF-A, reducing vascular permeability
and pathological neovascularization. Landmark trials (RISE/RIDE for
ranibizumab; VIVID/VISTA for aflibercept; PROTOCOL T) demonstrated superior
outcomes over macular laser for CI-DME, with 18–45% of patients gaining ≥15
ETDRS letters. Best outcomes require frequent injections and close monitoring;
real-world outcomes often fall short of trials due to treatment burden.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: anti-VEGF biologic
term:
id: NCIT:C20401
label: Monoclonal Antibody
evidence:
- reference: PMID:38264181
reference_title: "Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Anti-VEGF treatments, including ranibizumab, bevacizumab, and aflibercept, have revolutionized DME management by targeting VEGF, a key mediator in DME pathogenesis."
explanation: Review documents that anti-VEGF agents (ranibizumab, bevacizumab, aflibercept) have revolutionized DME management by targeting its key pathogenic mediator.
- reference: PMID:38995350
reference_title: "Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for the management of DME"
explanation: Review establishes intravitreal anti-VEGF as the current standard of care for DME management, though sustained treatment is required.
- reference: PMID:39717563
reference_title: "Outcomes of Anti-VEGF Therapy in Eyes with Diabetic Macular Edema, Vein Occlusion-Related Macular Edema, and Neovascular Age-Related Macular Degeneration: A Systematic Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Anti-VEGF therapy represents a cornerstone in the management of DME, RVO-related ME, and nAMD, with significant improvements observed in BCVA and reductions in CMT across diverse patient populations."
explanation: Systematic review concludes anti-VEGF therapy is a cornerstone for DME management with significant improvements in both visual acuity (BCVA) and anatomic outcomes (CMT reduction).
target_mechanisms:
- target: VEGF-Driven Retinal Neovascularization
treatment_effect: INHIBITS
description: Anti-VEGF agents neutralize VEGF-A, directly inhibiting pathological neovascularization in PDR and reducing vitreous hemorrhage risk.
- target: Blood-Retinal Barrier Breakdown
treatment_effect: INHIBITS
description: VEGF neutralization reduces vascular permeability, restoring BRB integrity and resolving macular edema in CI-DME.
target_phenotypes:
- preferred_term: Macular edema
term:
id: HP:0040049
label: Macular edema
- preferred_term: Vitreous hemorrhage
term:
id: HP:0007902
label: Vitreous hemorrhage
- name: Panretinal Laser Photocoagulation
description: >
Established standard of care for high-risk proliferative diabetic retinopathy
(PDR). Panretinal photocoagulation (PRP) ablates ischemic peripheral retina,
reducing the hypoxic stimulus for pathological VEGF production and causing
regression of neovascularization. Network meta-analysis of 14 RCTs found
anti-VEGF slightly superior to PRP for short-term visual acuity but PRP
remains the backbone long-term treatment for PDR, particularly where frequent
anti-VEGF injections cannot be sustained.
treatment_term:
preferred_term: laser photocoagulation
term:
id: NCIT:C49236
label: Therapeutic Procedure
evidence:
- reference: PMID:39673354
reference_title: "Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Panretinal photocoagulation is the primary treatment for proliferative diabetic retinopathy. Anti-vascular endothelial growth factor drugs are used to treat various eye conditions and may be beneficial for people with diabetic retinopathy."
explanation: HTA systematic review confirms PRP as the primary treatment for PDR and contextualizes anti-VEGF as an emerging alternative.
- reference: PMID:29776671
reference_title: "Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Vision loss from DR can be prevented with broad-level public health strategies, but these need to be tailored to a country's and population's resource setting."
explanation: ICO guidelines identify laser photocoagulation as a cost-effective treatment for vision-threatening DR, foundational to global prevention programs in resource-varied settings.
target_mechanisms:
- target: VEGF-Driven Retinal Neovascularization
treatment_effect: INHIBITS
description: PRP destroys ischemic peripheral retina, reducing VEGF production and causing regression of neovascular vessels in PDR.
target_phenotypes:
- preferred_term: Vitreous hemorrhage
term:
id: HP:0007902
label: Vitreous hemorrhage
- name: Pars Plana Vitrectomy
description: >
Surgical removal of the vitreous, indicated for non-clearing vitreous
hemorrhage, tractional retinal detachment involving or threatening the macula,
and severe fibrovascular proliferation in PDR. Restores optical clarity and
allows retinal reattachment. Altered pharmacokinetics in vitrectomized eyes
(faster clearance of intravitreal agents) may require modification of
anti-VEGF treatment intervals.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: PMID:29776671
reference_title: "Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "appropriate management of vision-threatening DR, including diabetic macular edema (DME) and proliferative DR, for countries with high- and low- or intermediate-resource settings"
explanation: ICO guidelines include surgical management (vitrectomy) among the options for vision-threatening PDR complications when other treatments are insufficient.
target_phenotypes:
- preferred_term: Vitreous hemorrhage
term:
id: HP:0007902
label: Vitreous hemorrhage
clinical_trials:
- name: NCT06662994
phase: PHASE_IV
status: RECRUITING
description: >
Phase 4 trial of high-dose aflibercept 8 mg using a treat-extend-stop
protocol in patients with center-involving DME after prior vitrectomy.
Investigates whether high-dose aflibercept improves anatomic and visual
outcomes in vitrectomized eyes, where faster drug clearance may reduce
standard-dose anti-VEGF efficacy.
target_phenotypes:
- preferred_term: Macular edema
term:
id: HP:0040049
label: Macular edema
evidence:
- reference: clinicaltrials:NCT06662994
reference_title: "High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy"
supports: SUPPORT
snippet: "Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues."
explanation: Phase 4 trial addressing high-dose aflibercept for DME in vitrectomized eyes, relevant to the altered pharmacokinetics and treatment challenges in advanced PDR/DME.
classifications:
harrisons_chapter:
- classification_value: ENDOCRINOLOGY_METABOLISM
evidence:
- reference: PMID:39550444
reference_title: "Prevalence of diabetic retinopathy and its associated risk factors among adults in Ethiopia: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Retinopathy affects one in four patients with diabetes. Diabetic patients with longer duration, hypertension, poor glycemic control, and positive proteinuria should receive special care."
explanation: Meta-analysis frames DR as a diabetes complication requiring special care, supporting classification under Endocrinology and Metabolism.
- reference: PMID:39651973
reference_title: "12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2025."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2025."
explanation: ADA Standards of Care section on retinopathy is organized within diabetes care guidelines, confirming DR classification as an endocrine-metabolic complication.
References & Deep Research
Deep Research
11. Disease Information
1.1 What is the disease?
The American Diabetes Association (ADA) Standards of Care describes DR as “a highly specific neurovascular complication of both type 1 and type 2 diabetes,” whose prevalence is strongly linked to diabetes duration and glycemic control. (elsayed202512.retinopathyneuropathy pages 1-1)
The International Council of Ophthalmology (ICO) guideline describes DR as “the most common specific microvascular complication of DM,” progressing from milder nonproliferative diabetic retinopathy (NPDR) to vision-threatening proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME). (wong2018guidelinesondiabetic pages 2-3)
1.2 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)
Within the tool-accessible corpus retrieved for this report, explicit ontology identifiers (MONDO ID, MeSH ID, ICD-10/ICD-11 codes, OMIM, Orphanet) were not available as citable evidence; therefore, they cannot be verified here and should be populated from external ontology resources (e.g., MONDO, MeSH, ICD-10/ICD-11 browsers). (No in-corpus evidence)
1.3 Synonyms and alternative names
Common clinical terms in guidelines and recent literature include: - Diabetic retinopathy (DR) (wong2018guidelinesondiabetic pages 2-3) - Nonproliferative diabetic retinopathy (NPDR) (wong2018guidelinesondiabetic pages 2-3, elsayed202512.retinopathyneuropathy pages 2-3) - Proliferative diabetic retinopathy (PDR) (wong2018guidelinesondiabetic pages 2-3, elsayed202512.retinopathyneuropathy pages 2-3) - Diabetic macular edema (DME) (wong2018guidelinesondiabetic pages 2-3) - Clinically significant macular edema (CSME; classic ETDRS term) (elsayed202512.retinopathyneuropathy pages 3-4)
1.4 Evidence source type
This report is derived from aggregated disease-level resources (international guidelines, systematic reviews, meta-analyses, epidemiologic studies, and clinical trial registry records) rather than individual-patient EHR-derived phenotypes. (wondmeneh2024prevalenceofdiabetic pages 12-15, wong2018guidelinesondiabetic pages 2-3, elsayed202512.retinopathyneuropathy pages 1-1, NCT02471651 chunk 1)
2. Etiology
2.1 Disease causal factors (mechanistic)
The etiologic driver is chronic diabetes-associated metabolic dysregulation (particularly hyperglycemia) leading to neurovascular retinal injury through oxidative stress and inflammatory pathways. Mechanistic reviews synthesize the cascade: hyperglycemia activates metabolic pathways (e.g., AGE formation, PKC activation), promoting ROS generation and inflammatory signaling, damaging pericytes/endothelial cells and destabilizing the BRB, which contributes to macular edema, ischemia, and neovascularization. (gomezjimenez2025modulationofoxidative pages 7-8, srejovic2024molecularandcellular pages 1-3, srejovic2024molecularandcellular pages 3-4)
2.2 Risk factors (human epidemiology)
ADA (risk-factor framing): DR prevalence relates strongly to diabetes duration and glycemic control, with additional associated factors including chronic hyperglycemia, nephropathy, hypertension, and dyslipidemia. (elsayed202512.retinopathyneuropathy pages 1-1)
Recent meta-analysis (Ethiopia, 2024): pooled DR prevalence in adults with diabetes was 24.35% (95% CI: 18.88–29.83), with key risk factors: - Diabetes duration ≥10 years: AOR 4.36 - Hypertension: AOR 2.54 - Poor glycemic control: AOR 3.83 - Positive proteinuria: AHR 1.55 (wondmeneh2024prevalenceofdiabetic pages 1-2, wondmeneh2024prevalenceofdiabetic pages 12-15)
2.3 Protective factors
Direct evidence for protective genetic variants or protective exposures was not captured in the retrieved corpus. The ADA/ICO guidelines emphasize risk reduction via achieving glycemic, blood pressure, and lipid targets, which functionally serve as protective measures against onset/progression. (wong2018guidelinesondiabetic pages 2-3, elsayed202512.retinopathyneuropathy pages 1-1)
2.4 Gene–environment interactions
Not explicitly quantified in the retrieved corpus. Mechanistic syntheses support an interaction model in which systemic metabolic exposures (hyperglycemia, dyslipidemia, hypertension) modulate inflammatory/oxidative pathways and vascular signaling (e.g., VEGF), which in turn shape disease expression. (gomezjimenez2025modulationofoxidative pages 7-8, srejovic2024molecularandcellular pages 1-3)
3. Phenotypes (clinical manifestations)
3.1 Core phenotypes and staging (ICO clinical taxonomy)
ICO describes DR microvascular lesions including “microaneurysms, intraretinal hemorrhages, venous beading…, intraretinal microvascular abnormalities, hard exudates…, and retinal neovascularization.” It also highlights that early DR is often asymptomatic and that advanced DR/DME can exist without visual symptoms. (wong2018guidelinesondiabetic pages 3-5)
DR staging terms: - No apparent DR → mild/moderate/severe NPDR → PDR (wong2018guidelinesondiabetic pages 2-3) - Key distinction: “Eyes with NPDR have not yet developed neovascularization.” (wong2018guidelinesondiabetic pages 3-5)
DME phenotypes and subtypes: ICO DME classification is explicitly defined by central macular involvement: - Nonecenter-involving DME: macular thickening not involving central 1 mm subfield - Center-involving DME: thickening involving central 1 mm subfield (wong2018guidelinesondiabetic pages 2-3)
CSME definition (ETDRS term used in ADA 2025): “retinal edema located at or threatening the macular center.” (elsayed202512.retinopathyneuropathy pages 3-4)
3.2 Suggested HPO terms (non-exhaustive; to be validated against HPO)
Because explicit HPO IDs are not provided in the retrieved sources, the following are suggested concept-level mappings: - Decreased visual acuity; visual impairment (supported by burden statements and DME context) (elsayed202512.retinopathyneuropathy pages 3-4, elsayed202512.retinopathyneuropathy pages 1-1) - Retinal hemorrhage / intraretinal hemorrhage; microaneurysm; retinal neovascularization (ICO lesion descriptions) (wong2018guidelinesondiabetic pages 3-5) - Macular edema / retinal edema (DME/CSME definitions) (elsayed202512.retinopathyneuropathy pages 3-4, wong2018guidelinesondiabetic pages 2-3)
3.3 Quality of life impact
ADA notes population-level functional consequences: in the U.S., ~12% of adults with diabetes have some level of vision impairment, and diabetes increases risk of chronic vision loss and functional decline. (elsayed202512.retinopathyneuropathy pages 3-4)
4. Genetic / Molecular Information
4.1 Genetic architecture (current evidence availability)
The retrieved evidence set does not provide validated causal germline variants or a curated list of DR causal genes with OMIM IDs; DR is generally treated as a complex complication with multifactorial etiology in this corpus. (No in-corpus variant evidence)
4.2 Disease–target associations (Open Targets)
Open Targets identifies disease–target associations for “diabetic retinopathy,” including VEGFA and PGF (among others such as ANGPT2 and NR3C1), with evidence including clinical-stage associations and literature links. (OpenTargets Search: diabetic retinopathy)
Interpretation: These targets align with established therapeutic biology (anti-VEGF agents; emerging Ang-2/Tie2 biology), but Open Targets associations are not equivalent to confirmed causal germline genetics. (OpenTargets Search: diabetic retinopathy, srejovic2024molecularandcellular pages 1-3)
4.3 Epigenetics / metabolic memory
Mechanistic reviews describe persistent oxidative/inflammatory signaling and “metabolic memory” concepts, where prior hyperglycemic exposure can sustain downstream pathology even after improved glycemia. (gomezjimenez2025modulationofoxidative pages 7-8)
5. Environmental Information
5.1 Non-genetic contributing factors (lifestyle/clinical)
Key modifiable systemic exposures emphasized in guidelines and epidemiology include chronic hyperglycemia, hypertension, dyslipidemia, and nephropathy/proteinuria. (wondmeneh2024prevalenceofdiabetic pages 1-2, elsayed202512.retinopathyneuropathy pages 1-1)
5.2 Infectious agents
Not applicable based on retrieved evidence. (No in-corpus evidence)
6. Mechanism / Pathophysiology
6.1 Causal chain (integrated model)
A coherent causal chain supported across mechanistic reviews is: 1) Diabetes-associated hyperglycemia and metabolic dysregulation 2) Activation of oxidative stress and inflammatory pathways (ROS generation; NF-κB signaling) 3) Retinal vascular dysfunction (pericyte/endothelial injury; tight junction disruption) 4) BRB breakdown → increased vascular permeability → macular edema (DME) 5) Capillary closure/ischemia → pro-angiogenic signaling (VEGF) → neovascularization (PDR) (gomezjimenez2025modulationofoxidative pages 7-8, srejovic2024molecularandcellular pages 1-3, srejovic2024molecularandcellular pages 3-4)
6.2 Key pathways and molecular mediators
- VEGF is described as a central driver of abnormal neovascularization and a major therapeutic target in retinal vascular disease, including DR. (srejovic2024molecularandcellular pages 1-3)
- ANGPT2–Tie2 axis: “Interaction between angiopoietin 2 and the Tie2 receptor results in aberrant Tie2 signaling, resulting in loss of pericytes, neovascularization, and inflammation.” (srejovic2024molecularandcellular pages 1-3)
- Inflammatory cytokines and microglia: Increased TNF-α, IL-1β, and IL-6 and microglial activation contribute to a persistent inflammatory milieu promoting BRB breakdown and neovascularization. (srejovic2024molecularandcellular pages 1-3)
- Oxidative stress/ROS: Oxidative stress is repeatedly positioned as a central driver connecting metabolic dysregulation to retinal injury and neurovascular dysfunction; NLRP3 inflammasome and autophagy appear as research hotspots. (gomezjimenez2025modulationofoxidative pages 7-8, du2024globalresearchtrends pages 1-2)
6.3 Cell types and ontology suggestions
Cell types (suggested CL concepts; IDs not available in corpus): - Retinal pericytes (pericyte loss emphasized) (srejovic2024molecularandcellular pages 1-3) - Retinal vascular endothelial cells (vascular dysfunction; BRB breakdown) (srejovic2024molecularandcellular pages 1-3, srejovic2024molecularandcellular pages 3-4) - Microglia (activation; inflammatory milieu) (srejovic2024molecularandcellular pages 1-3) - Müller glia (implicated in inflammasome/pyroptosis pathways in mechanistic review synthesis) (gomezjimenez2025modulationofoxidative pages 7-8)
GO biological process concepts (suggested): angiogenesis, inflammatory response, response to oxidative stress, regulation of vascular permeability, cytokine-mediated signaling pathway. (gomezjimenez2025modulationofoxidative pages 7-8, srejovic2024molecularandcellular pages 1-3)
7. Anatomical Structures Affected
7.1 Organ/tissue localization
Primary affected structure is the retina, including the macula (DME) and retinal vasculature (NPDR/PDR). BRB components are explicitly discussed (inner BRB via retinal vascular endothelium; outer BRB via RPE in general retinal vascular disease frameworks). (srejovic2024molecularandcellular pages 1-3, wong2018guidelinesondiabetic pages 2-3)
Suggested UBERON concepts (IDs not available in corpus): retina; macula; retinal blood vessel; vitreous body (relevant to vitreous hemorrhage and tractional detachment risk in PDR context). (wong2018guidelinesondiabetic pages 3-5, simmonds2024antivegfdrugscompared pages 25-27)
7.2 Laterality
DR is typically bilateral (diabetes-related systemic exposure), but explicit laterality assertions were not provided in the retrieved corpus. (No in-corpus evidence)
8. Temporal Development
8.1 Onset pattern
ICO emphasizes that DR “develops over time” and that early disease may be asymptomatic, supporting an insidious onset. (wong2018guidelinesondiabetic pages 2-3, wong2018guidelinesondiabetic pages 3-5)
8.2 Progression
ICO explicitly frames progression from NPDR to PDR/DME and notes that PDR is an angiogenic response to extensive ischemia from capillary closure, consistent with stepwise worsening in untreated disease. (wong2018guidelinesondiabetic pages 2-3)
9. Inheritance and Population
9.1 Epidemiology (recent statistics)
- Global burden of blindness due to DR (1990–2021): number of people blind due to DR increased 326.0%, and age-standardized prevalence rate rose from 7.59 to 15.28 per 100,000 population. (Meng et al., 2025; https://doi.org/10.1007/s40123-025-01230-y) (meng2025globalregionaland pages 1-2)
- Ethiopia (systematic review/meta-analysis, 2024): pooled DR prevalence 24.35% (95% CI: 18.88–29.83), summarized as “one in four” people with diabetes. (Wondmeneh & Mohammed, 2024; https://doi.org/10.1038/s41598-024-78596-9) (wondmeneh2024prevalenceofdiabetic pages 1-2, wondmeneh2024prevalenceofdiabetic pages 12-15)
- ICO contextual estimate (global): “approximately 1 in 3 persons with DM has DR, and 1 in 10 has PDR or DME.” (Wong et al., 2018; https://doi.org/10.1016/j.ophtha.2018.04.007) (wong2018guidelinesondiabetic pages 1-2)
9.2 Inheritance pattern
Not applicable as a monogenic inheritance pattern in this evidence set; DR is treated as a complex complication. (No in-corpus evidence)
10. Diagnostics
10.1 Screening and diagnostic modalities (guideline-based)
ADA Standards of Care (2025): - Initial eye exam timing: - Type 1 diabetes: “within 5 years after the diagnosis of diabetes” (dilated, comprehensive). (elsayed202512.retinopathyneuropathy pages 2-3) - Type 2 diabetes: “at the time of diagnosis.” (elsayed202512.retinopathyneuropathy pages 2-3) - Follow-up: - Generally annual for none/mild retinopathy; “screening every 1–2 years may be considered” in selected low-risk scenarios after normal exams and if glycemic indicators are at goal. (elsayed202512.retinopathyneuropathy pages 1-2) - Implementation: validated retinal photography programs with trained readers; FDA-approved autonomous AI systems may be used where appropriate (e.g., EyeArt, LumineticsCore, AEYE-DS), but abnormal/ungradable images require in-person eye examination. (elsayed202512.retinopathyneuropathy pages 1-2)
Image evidence: the ADA recommendations box summarizing these screening statements is available as a cropped guideline image. (elsayed202512.retinopathyneuropathy media 6876c524)
ICO (resource-stratified) follow-up intervals (high-resource example): - No apparent DR or mild NPDR (no DME): re-examination in 1–2 years - Moderate NPDR: 3–6 months - PDR: <1 month and DME classification into center-involving vs nonecenter-involving by clinical findings and OCT (if available). (wong2018guidelinesondiabetic pages 7-9, wong2018guidelinesondiabetic pages 2-3)
10.2 Differential diagnosis
Not extracted from the retrieved corpus. (No in-corpus evidence)
10.3 Omics-based diagnostics
Not supported by direct evidence in the retrieved corpus (though mechanistic reviews discuss biomarkers conceptually). (toma2026oxidativestressin pages 1-2)
11. Outcome / Prognosis
11.1 Vision loss and blindness
- ADA states DR is “the most frequent cause of new cases of blindness among adults aged 20–74 years in developed countries.” (elsayed202512.retinopathyneuropathy pages 1-1)
- Global DR-related blindness burden has increased substantially over recent decades (1990–2021). (meng2025globalregionaland pages 1-2)
11.2 Prognostic factors
Systemic risk-factor control (glycemia, blood pressure, lipids) is positioned as central to slowing progression, and more frequent ophthalmologic follow-up is required when retinopathy is progressing or in the presence of DME/advanced disease. (elsayed202512.retinopathyneuropathy pages 2-3, elsayed202512.retinopathyneuropathy pages 1-1)
12. Treatment
12.1 Standard-of-care ocular treatments
- Anti-VEGF therapy is a cornerstone for DME, particularly center-involving DME, and is supported as more effective than laser monotherapy for center-involved DME in ADA discussion. (elsayed202512.retinopathyneuropathy pages 3-4)
- Panretinal photocoagulation (PRP) remains indicated for high-risk PDR (and selected severe NPDR) to reduce risk of vision loss. (elsayed202512.retinopathyneuropathy pages 2-3)
12.2 Quantitative treatment outcomes (recent syntheses)
Anti-VEGF in DME (systematic review, 2024): proportion gaining ≥15 ETDRS letters ranged 18.1%–44.8%, with central macular thickness reductions commonly in the range of 183.1–294 µm (across DME/RVO cohorts). (Aldokhail et al., 2024; https://doi.org/10.2147/OPTH.S489114) (aldokhail2024outcomesofantivegf pages 1-2)
Trial-based outcomes summarized in 2024 review: ranibizumab RISE/RIDE reported 40–44% gaining ≥15 ETDRS letters vs 20% with sham at 3 years, with CMT reductions about −261 to −269 μm. (Cheema & Cheema, 2024; https://doi.org/10.7759/cureus.52676) (cheema2024diabeticmacularedema pages 5-7)
Real-world implementation challenge: a 2024 review emphasizes that trial vision gains depend on frequent injections/monitoring and that real-world outcomes are often poorer because maintaining frequent injection schedules is difficult. (Nakao et al., 2024; https://doi.org/10.1007/s00417-024-06558-y) (nakao2024antivegftherapyfor pages 1-2)
Anti-VEGF vs PRP in DR (Health Technology Assessment, 2024): network meta-analysis across 14 RCTs found anti-VEGF “slightly better” than PRP for BCVA up to 2 years (mean difference −0.089 logMAR ≈ 3.6 ETDRS letters) and reduced macular edema (RR 0.29; 95% CI 0.18–0.49) and vitreous hemorrhage (RR 0.77; 95% CI 0.61–0.99); authors concluded the BCVA benefit is small and may not be clinically meaningful. (Simmonds et al., 2024; https://doi.org/10.3310/pcgv5709) (wong2018guidelinesondiabetic pages 1-2)
12.3 Systemic therapies and risk-factor modification
ICO and ADA emphasize maintenance of glycemic control and management of hypertension and dyslipidemia as core strategies to reduce risk and slow progression. (wong2018guidelinesondiabetic pages 2-3, elsayed202512.retinopathyneuropathy pages 1-1)
12.4 Examples of recent/ongoing/illustrative clinical trials (ClinicalTrials.gov)
- NCT06662994 (2025; Phase 4; Recruiting): high-dose aflibercept 8 mg in central-involving DME after prior vitrectomy, using a treat–extend–stop protocol; outcomes include visual acuity and OCT thickness over 12 months. (https://clinicaltrials.gov/study/NCT06662994) (NCT06662994 chunk 2, NCT06662994 chunk 1)
- NCT02471651 (2015; Phase 4; Completed): dexamethasone intravitreal implant (Ozurdex 0.7 mg) vs continued monthly anti-VEGF for persistent DME after prior anti-VEGF; primary endpoint central 1 mm subfield thickness change. (https://clinicaltrials.gov/study/NCT02471651) (NCT02471651 chunk 1)
- NCT07144865 (2024; Completed; phase not specified in excerpt): evaluates biological changes in fibrovascular membranes in PDR following faricimab injection (relevant to dual-pathway anti-VEGF/Ang-2 strategies). (https://clinicaltrials.gov/study/NCT07144865) (NCT07144865 chunk 2)
12.5 MAXO suggestions (concept-level; IDs not available in corpus)
- Intravitreal injection of anti-VEGF agent (elsayed202512.retinopathyneuropathy pages 3-4)
- Panretinal photocoagulation (elsayed202512.retinopathyneuropathy pages 2-3)
- Focal/grid laser photocoagulation (macular edema context) (elsayed202512.retinopathyneuropathy pages 3-4)
- Vitrectomy (vision-threatening complications context in ICO) (wong2018guidelinesondiabetic pages 1-2)
13. Prevention
Primary/secondary prevention framing: DR is preventable and progression-reducible through systemic risk-factor control and systematic screening programs. - ICO explicitly states that “Vision loss from DR can be prevented with broad-level public health strategies,” and both ICO and ADA emphasize glycemic and cardiovascular risk control. (wong2018guidelinesondiabetic pages 1-2, elsayed202512.retinopathyneuropathy pages 1-1) - ADA screening intervals (type 1 within 5 years; type 2 at diagnosis; generally annual thereafter with risk-stratified extension to 1–2 years) operationalize secondary prevention via early detection and timely referral. (elsayed202512.retinopathyneuropathy pages 2-3, elsayed202512.retinopathyneuropathy pages 1-2, elsayed202512.retinopathyneuropathy media 6876c524)
14. Other Species / Natural Disease
No veterinary/natural disease evidence was retrieved in the tool-accessible corpus for this report. (No in-corpus evidence)
15. Model Organisms
No model-organism–specific evidence was retrieved in the tool-accessible corpus for this report. (No in-corpus evidence)
Recent developments and real-world implementations (2023–2024 emphasis)
1) AI-enabled and teleophthalmology screening is now guideline-referenced and increasingly deployed. ADA 2025 includes FDA-approved autonomous AI systems (e.g., EyeArt, LumineticsCore, AEYE-DS) as acceptable screening approaches when implemented with validated workflows and appropriate referral for abnormal/ungradable results. (elsayed202512.retinopathyneuropathy pages 1-2)
2) Low-cost imaging implementations are being clinically validated. A 2023 multicenter validation study found a smartphone-based/handheld fundus camera performed comparably to tabletop cameras for DR/DME screening with substantial agreement and high sensitivity/specificity for referable DR, supporting expansion of screening coverage in resource-limited settings. (de Oliveira et al., 2023; https://doi.org/10.1007/s00592-023-02105-z) (paper retrieved; see artifact row) (wong2018guidelinesondiabetic pages 1-2)
3) Therapeutic development is shifting toward durability and multi-pathway targeting. Mechanistic reviews and Open Targets associations highlight VEGF (VEGFA) and ANGPT2 biology, consistent with interest in dual-pathway approaches (e.g., faricimab) and in treating inflammation/oxidative stress upstream of late-stage vascular manifestations. (OpenTargets Search: diabetic retinopathy, srejovic2024molecularandcellular pages 1-3)
Key limitations of this report (evidence gaps in tool-accessible corpus)
- Explicit ICD/ICD-11, MeSH, OMIM, Orphanet, and MONDO identifiers were not available as citable evidence in the retrieved corpus. (No in-corpus evidence)
- Variant-level genetics, protective factors, and formal gene–environment interaction studies were not captured in the retrieved evidence set, beyond target associations and mechanistic pathway discussions. (OpenTargets Search: diabetic retinopathy, gomezjimenez2025modulationofoxidative pages 7-8)
- Model-organism and cross-species disease evidence was not retrieved. (No in-corpus evidence)
URLs and publication dates (high-value sources)
- ADA Standards of Care in Diabetes—2025 (Diabetes Care; Dec 2025): https://doi.org/10.2337/dc25-s012 (elsayed202512.retinopathyneuropathy pages 2-3)
- ICO/International Council of Ophthalmology diabetic eye care guideline (Ophthalmology; May 2018): https://doi.org/10.1016/j.ophtha.2018.04.007 (wong2018guidelinesondiabetic pages 2-3)
- Ethiopia DR prevalence + risk factors meta-analysis (Scientific Reports; Nov 2024): https://doi.org/10.1038/s41598-024-78596-9 (wondmeneh2024prevalenceofdiabetic pages 1-2)
- Global blindness due to DR (Ophthalmology and Therapy; Aug 2025): https://doi.org/10.1007/s40123-025-01230-y (meng2025globalregionaland pages 1-2)
- Anti-VEGF outcomes synthesis (Clinical Ophthalmology; Dec 2024): https://doi.org/10.2147/OPTH.S489114 (aldokhail2024outcomesofantivegf pages 1-2)
- Anti-VEGF vs PRP HTA (Dec 2024): https://doi.org/10.3310/pcgv5709 (wong2018guidelinesondiabetic pages 1-2)
- DME treat-to-target/real-world burden review (Jul 2024): https://doi.org/10.1007/s00417-024-06558-y (nakao2024antivegftherapyfor pages 1-2)
- Example trial: NCT06662994: https://clinicaltrials.gov/study/NCT06662994 (NCT06662994 chunk 2)
References
-
(srejovic2024molecularandcellular pages 1-3): Jovana V. Srejovic, Maja D. Muric, Vladimir Lj. Jakovljevic, Ivan M. Srejovic, Suncica B. Sreckovic, Nenad T. Petrovic, Dusan Z. Todorovic, Sergey B. Bolevich, and Tatjana S. Sarenac Vulovic. Molecular and cellular mechanisms involved in the pathophysiology of retinal vascular disease—interplay between inflammation and oxidative stress. International Journal of Molecular Sciences, 25:11850, Nov 2024. URL: https://doi.org/10.3390/ijms252111850, doi:10.3390/ijms252111850. This article has 63 citations.
-
(wong2018guidelinesondiabetic pages 2-3): T. Wong, Jennifer K. Sun, R. Kawasaki, Paisan Ruamviboonsuk, N. Gupta, V. Lansingh, M. Maia, Wanjiku Mathenge, Sunil Moreker, Mahi M K Muqit, S. Resnikoff, J. Verdaguer, Peiquan Zhao, F. Ferris, L. Aiello, and H. Taylor. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology, 125 10:1608-1622, May 2018. URL: https://doi.org/10.1016/j.ophtha.2018.04.007, doi:10.1016/j.ophtha.2018.04.007. This article has 1088 citations and is from a highest quality peer-reviewed journal.
-
(elsayed202512.retinopathyneuropathy pages 1-1): Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Robert G. Frykberg, Rajesh Garg, Sunir J. Garg, John M. Giurini, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, and Raveendhara R. Bannuru. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes—2025. Diabetes Care, 48:S252-S265, Dec 2025. URL: https://doi.org/10.2337/dc25-s012, doi:10.2337/dc25-s012. This article has 146 citations and is from a highest quality peer-reviewed journal.
-
(wong2018guidelinesondiabetic pages 1-2): T. Wong, Jennifer K. Sun, R. Kawasaki, Paisan Ruamviboonsuk, N. Gupta, V. Lansingh, M. Maia, Wanjiku Mathenge, Sunil Moreker, Mahi M K Muqit, S. Resnikoff, J. Verdaguer, Peiquan Zhao, F. Ferris, L. Aiello, and H. Taylor. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology, 125 10:1608-1622, May 2018. URL: https://doi.org/10.1016/j.ophtha.2018.04.007, doi:10.1016/j.ophtha.2018.04.007. This article has 1088 citations and is from a highest quality peer-reviewed journal.
-
(wong2018guidelinesondiabetic pages 7-9): T. Wong, Jennifer K. Sun, R. Kawasaki, Paisan Ruamviboonsuk, N. Gupta, V. Lansingh, M. Maia, Wanjiku Mathenge, Sunil Moreker, Mahi M K Muqit, S. Resnikoff, J. Verdaguer, Peiquan Zhao, F. Ferris, L. Aiello, and H. Taylor. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology, 125 10:1608-1622, May 2018. URL: https://doi.org/10.1016/j.ophtha.2018.04.007, doi:10.1016/j.ophtha.2018.04.007. This article has 1088 citations and is from a highest quality peer-reviewed journal.
-
(wong2018guidelinesondiabetic pages 3-5): T. Wong, Jennifer K. Sun, R. Kawasaki, Paisan Ruamviboonsuk, N. Gupta, V. Lansingh, M. Maia, Wanjiku Mathenge, Sunil Moreker, Mahi M K Muqit, S. Resnikoff, J. Verdaguer, Peiquan Zhao, F. Ferris, L. Aiello, and H. Taylor. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology, 125 10:1608-1622, May 2018. URL: https://doi.org/10.1016/j.ophtha.2018.04.007, doi:10.1016/j.ophtha.2018.04.007. This article has 1088 citations and is from a highest quality peer-reviewed journal.
-
(meng2025globalregionaland pages 1-2): Yang Meng, Yuan Liu, Yuan Ma, Ziye Chen, Runping Duan, Lan Jiang, and Tao Li. Global, regional, and national burden of blindness due to diabetic retinopathy, 1990–2021. Ophthalmology and Therapy, 14:2599-2615, Aug 2025. URL: https://doi.org/10.1007/s40123-025-01230-y, doi:10.1007/s40123-025-01230-y. This article has 6 citations and is from a peer-reviewed journal.
-
(wondmeneh2024prevalenceofdiabetic pages 1-2): Temesgen Gebeyehu Wondmeneh and Jemal Abdu Mohammed. Prevalence of diabetic retinopathy and its associated risk factors among adults in ethiopia: a systematic review and meta-analysis. Scientific Reports, Nov 2024. URL: https://doi.org/10.1038/s41598-024-78596-9, doi:10.1038/s41598-024-78596-9. This article has 24 citations and is from a peer-reviewed journal.
-
(wondmeneh2024prevalenceofdiabetic pages 12-15): Temesgen Gebeyehu Wondmeneh and Jemal Abdu Mohammed. Prevalence of diabetic retinopathy and its associated risk factors among adults in ethiopia: a systematic review and meta-analysis. Scientific Reports, Nov 2024. URL: https://doi.org/10.1038/s41598-024-78596-9, doi:10.1038/s41598-024-78596-9. This article has 24 citations and is from a peer-reviewed journal.
-
(elsayed202512.retinopathyneuropathy pages 2-3): Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Robert G. Frykberg, Rajesh Garg, Sunir J. Garg, John M. Giurini, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, and Raveendhara R. Bannuru. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes—2025. Diabetes Care, 48:S252-S265, Dec 2025. URL: https://doi.org/10.2337/dc25-s012, doi:10.2337/dc25-s012. This article has 146 citations and is from a highest quality peer-reviewed journal.
-
(elsayed202512.retinopathyneuropathy pages 1-2): Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Robert G. Frykberg, Rajesh Garg, Sunir J. Garg, John M. Giurini, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, and Raveendhara R. Bannuru. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes—2025. Diabetes Care, 48:S252-S265, Dec 2025. URL: https://doi.org/10.2337/dc25-s012, doi:10.2337/dc25-s012. This article has 146 citations and is from a highest quality peer-reviewed journal.
-
(elsayed202512.retinopathyneuropathy media 6876c524): Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Robert G. Frykberg, Rajesh Garg, Sunir J. Garg, John M. Giurini, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, and Raveendhara R. Bannuru. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes—2025. Diabetes Care, 48:S252-S265, Dec 2025. URL: https://doi.org/10.2337/dc25-s012, doi:10.2337/dc25-s012. This article has 146 citations and is from a highest quality peer-reviewed journal.
-
(gomezjimenez2025modulationofoxidative pages 7-8): Verónica Gómez-Jiménez, R. Burggraaf-Sánchez de Las Matas, and Ángel Luis Ortega. Modulation of oxidative stress in diabetic retinopathy: therapeutic role of natural polyphenols. Antioxidants, Jul 2025. URL: https://doi.org/10.3390/antiox14070875, doi:10.3390/antiox14070875. This article has 18 citations.
-
(toma2026oxidativestressin pages 1-2): Caterina Toma, Diego Ferdeghini, Mohammad Mostafa Ola Pour, Sakthipriyan Venkatesan, Stefano De Cillà, and Elena Grossini. Oxidative stress in diabetic retinopathy: pathogenic mechanisms, biomarkers and clinical implications. Antioxidants, 15:425, Mar 2026. URL: https://doi.org/10.3390/antiox15040425, doi:10.3390/antiox15040425. This article has 1 citations.
-
(roy2025pathophysiologicalmechanismsof pages 23-24): Bipradas Roy. Pathophysiological mechanisms of diabetes-induced macrovascular and microvascular complications: the role of oxidative stress. Medical Sciences, Jul 2025. URL: https://doi.org/10.3390/medsci13030087, doi:10.3390/medsci13030087. This article has 72 citations.
-
(srejovic2024molecularandcellular pages 3-4): Jovana V. Srejovic, Maja D. Muric, Vladimir Lj. Jakovljevic, Ivan M. Srejovic, Suncica B. Sreckovic, Nenad T. Petrovic, Dusan Z. Todorovic, Sergey B. Bolevich, and Tatjana S. Sarenac Vulovic. Molecular and cellular mechanisms involved in the pathophysiology of retinal vascular disease—interplay between inflammation and oxidative stress. International Journal of Molecular Sciences, 25:11850, Nov 2024. URL: https://doi.org/10.3390/ijms252111850, doi:10.3390/ijms252111850. This article has 63 citations.
-
(du2024globalresearchtrends pages 1-2): Kejie Du, Yichong Liu, Xintong Zhao, Haowen Wang, Xiaomei Wan, Xiaoyan Sun, and Wenjuan Luo. Global research trends and hotspots of oxidative stress in diabetic retinopathy (2000-2024). Frontiers in Endocrinology, Aug 2024. URL: https://doi.org/10.3389/fendo.2024.1428411, doi:10.3389/fendo.2024.1428411. This article has 6 citations.
-
(elsayed202512.retinopathyneuropathy pages 3-4): Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Brian C. Callaghan, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Robert G. Frykberg, Rajesh Garg, Sunir J. Garg, John M. Giurini, Kamlesh Khunti, Rayhan Lal, Ildiko Lingvay, Glenn Matfin, Naushira Pandya, Elizabeth J. Pekas, Scott J. Pilla, Sarit Polsky, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, and Raveendhara R. Bannuru. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes—2025. Diabetes Care, 48:S252-S265, Dec 2025. URL: https://doi.org/10.2337/dc25-s012, doi:10.2337/dc25-s012. This article has 146 citations and is from a highest quality peer-reviewed journal.
-
(cheema2024diabeticmacularedema pages 5-7): Abdullah A Cheema and Haider R Cheema. Diabetic macular edema management: a review of anti-vascular endothelial growth factor (vegf) therapies. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.52676, doi:10.7759/cureus.52676. This article has 56 citations.
-
(aldokhail2024outcomesofantivegf pages 1-2): Laila Aldokhail, Abdulaziz Alhadlaq, Lujain Alaradi, Lamees Alaradi, and Fatimah AlShaikh. Outcomes of anti-vegf therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review. Clinical Ophthalmology (Auckland, N.Z.), 18:3837-3851, Dec 2024. URL: https://doi.org/10.2147/opth.s489114, doi:10.2147/opth.s489114. This article has 23 citations.
-
(aldokhail2024outcomesofantivegf pages 4-5): Laila Aldokhail, Abdulaziz Alhadlaq, Lujain Alaradi, Lamees Alaradi, and Fatimah AlShaikh. Outcomes of anti-vegf therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review. Clinical Ophthalmology (Auckland, N.Z.), 18:3837-3851, Dec 2024. URL: https://doi.org/10.2147/opth.s489114, doi:10.2147/opth.s489114. This article has 23 citations.
-
(nakao2024antivegftherapyfor pages 1-2): Shintaro Nakao, Sentaro Kusuhara, and Tomoaki Murakami. Anti-vegf therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology. Graefe's Archive for Clinical and Experimental Ophthalmology, 262:3749-3759, Jul 2024. URL: https://doi.org/10.1007/s00417-024-06558-y, doi:10.1007/s00417-024-06558-y. This article has 22 citations.
-
(NCT02471651 chunk 1): Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema. California Retina Consultants. 2015. ClinicalTrials.gov Identifier: NCT02471651
-
(OpenTargets Search: diabetic retinopathy): Open Targets Query (diabetic retinopathy, 28 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
-
(simmonds2024antivegfdrugscompared pages 25-27): Mark Simmonds, Alexis Llewellyn, Ruth Walker, Helen Fulbright, Matthew Walton, Rob Hodgson, Laura Bojke, Lesley Stewart, Sofia Dias, Thomas Rush, John G Lawrenson, Tunde Peto, and David Steel. Anti-vegf drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis. Health technology assessment, pages 1-71, Dec 2024. URL: https://doi.org/10.3310/pcgv5709, doi:10.3310/pcgv5709. This article has 17 citations and is from a peer-reviewed journal.
-
(NCT06662994 chunk 2): High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy. Retina Consultants of Orange County. 2025. ClinicalTrials.gov Identifier: NCT06662994
-
(NCT06662994 chunk 1): High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy. Retina Consultants of Orange County. 2025. ClinicalTrials.gov Identifier: NCT06662994
-
(NCT07144865 chunk 2): Bojie Hu. Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection. Bojie Hu. 2024. ClinicalTrials.gov Identifier: NCT07144865
